The Next 10 Years in Atrial Fibrillation
Predicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Radcliffe Medical Media
2019-01-01
|
| Series: | US Cardiology Review |
| Online Access: | https://www.uscjournal.com/articles/10-years-atrial-fibrillation |
| _version_ | 1797200113127391232 |
|---|---|
| author | Jeffrey L Turner Nassir Marrouche |
| author_facet | Jeffrey L Turner Nassir Marrouche |
| author_sort | Jeffrey L Turner |
| collection | DOAJ |
| description | Predicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far from perfect. Over the next decade we expect significant continued progress in AF management. However, if asked to forecast the future, we consider it wise to predict advancements in the nearer term. We believe there will be widespread expansion in digital health and mobile devices, altering the way we detect and monitor the arrhythmia. We expect substantial growth in advanced MRI to aid in early detection, evaluation, and possibly non-invasive treatment of AF substrate. We imagine there will be increasing focus on individual populations to identify at-risk groups and personalize early management. We also anticipate improvement in anticoagulation employment and left atrial appendage modification. Finally, recognizing the benefit of improvement in modifiable risk factors such as mandatory tobacco cessation and weight loss in obese patients, we predict that reimbursement will be dependent on successfully addressing modifiable risk. For now, several questions remain unanswered, and while no one can predict the next 10 years in AF, there is, without doubt, an abundance of opportunity. |
| first_indexed | 2024-03-07T17:41:54Z |
| format | Article |
| id | doaj.art-55fab9d19d034ce39a86a21f63a95b72 |
| institution | Directory Open Access Journal |
| issn | 1758-3896 1758-390X |
| language | English |
| last_indexed | 2024-04-24T07:26:29Z |
| publishDate | 2019-01-01 |
| publisher | Radcliffe Medical Media |
| record_format | Article |
| series | US Cardiology Review |
| spelling | doaj.art-55fab9d19d034ce39a86a21f63a95b722024-04-20T16:01:12ZengRadcliffe Medical MediaUS Cardiology Review1758-38961758-390X2019-01-01131545710.15420/usc.2018.21.2The Next 10 Years in Atrial FibrillationJeffrey L Turner0Nassir Marrouche1Comprehensive Arrhythmia and Research Management Center, University of Utah School of Medicine, Salt Lake City, UTComprehensive Arrhythmia and Research Management Center, University of Utah School of Medicine, Salt Lake City, UTPredicting future advancements in arrhythmia management – specifically AF – with any certainty is impossible. The clinical approach to AF has changed markedly since the turn of the century in ways that could never have been foreseen, but the current methods of identification and treatment remain far from perfect. Over the next decade we expect significant continued progress in AF management. However, if asked to forecast the future, we consider it wise to predict advancements in the nearer term. We believe there will be widespread expansion in digital health and mobile devices, altering the way we detect and monitor the arrhythmia. We expect substantial growth in advanced MRI to aid in early detection, evaluation, and possibly non-invasive treatment of AF substrate. We imagine there will be increasing focus on individual populations to identify at-risk groups and personalize early management. We also anticipate improvement in anticoagulation employment and left atrial appendage modification. Finally, recognizing the benefit of improvement in modifiable risk factors such as mandatory tobacco cessation and weight loss in obese patients, we predict that reimbursement will be dependent on successfully addressing modifiable risk. For now, several questions remain unanswered, and while no one can predict the next 10 years in AF, there is, without doubt, an abundance of opportunity.https://www.uscjournal.com/articles/10-years-atrial-fibrillation |
| spellingShingle | Jeffrey L Turner Nassir Marrouche The Next 10 Years in Atrial Fibrillation US Cardiology Review |
| title | The Next 10 Years in Atrial Fibrillation |
| title_full | The Next 10 Years in Atrial Fibrillation |
| title_fullStr | The Next 10 Years in Atrial Fibrillation |
| title_full_unstemmed | The Next 10 Years in Atrial Fibrillation |
| title_short | The Next 10 Years in Atrial Fibrillation |
| title_sort | next 10 years in atrial fibrillation |
| url | https://www.uscjournal.com/articles/10-years-atrial-fibrillation |
| work_keys_str_mv | AT jeffreylturner thenext10yearsinatrialfibrillation AT nassirmarrouche thenext10yearsinatrialfibrillation AT jeffreylturner next10yearsinatrialfibrillation AT nassirmarrouche next10yearsinatrialfibrillation |